Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

BACKGROUND: In breast cancers, only a minority of patients fully benefit from the different chemotherapy regimens currently in use. Identification of markers that could predict the response to a particular regimen would thus be critically important for patient care. In cell lines or animal models, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertheau, Philippe, Turpin, Elisabeth, Rickman, David S, Espié, Marc, de Reyniès, Aurélien, Feugeas, Jean-Paul, Plassa, Louis-François, Soliman, Hany, Varna, Mariana, de Roquancourt, Anne, Lehmann-Che, Jacqueline, Beuzard, Yves, Marty, Michel, Misset, Jean-Louis, Janin, Anne, de Thé, Hugues
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1831731/
https://www.ncbi.nlm.nih.gov/pubmed/17388661
http://dx.doi.org/10.1371/journal.pmed.0040090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1831731/
https://www.ncbi.nlm.nih.gov/pubmed/17388661
http://dx.doi.org/10.1371/journal.pmed.0040090

Ejemplares similares